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NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
First-Generation Epidermal Growth Factor Receptor
Tyrosine Kinase Inhibitors in EGFR Mutation
Positive Non-small Cell Lung Cancer Patients
Lecia V. Sequist, MD, MPH
Small molecule tyrosine kinase inhibitors of the epidermal growth
factor receptor (EGFR) are important agents in the treatment of
non-small cell lung cancer (NSCLC) and have enhanced activity in
the subpopulation of patients with NSCLC who harbor somatic
activating mutations of the EGFR gene. This review summarizes the
data describing the use of EGFR tyrosine kinase inhibitors in a
genotype-directed population of NSCLC patients with EGFR muta-
tions and discusses areas that require further study.
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Advanced non-small cell lung cancer (NSCLC) is anaggressive malignancy that causes more than 165,000
deaths per year.1 Small molecule tyrosine kinase inhibitors
(TKIs) targeted against the epidermal growth factor receptor
(EGFR) have made a significant impact on the treatment of
advanced NSCLC. For patients with advanced NSCLC who
have previously received chemotherapy, the first-generation
EGFR TKI agents gefitinib and erlotinib led to a response in
10 to 18%, erlotinib improves median survival by 2 months
compared with placebo, and gefitinib has been shown to be
noninferior to docetaxel.2–6 Erlotinib is approved for use in
NSCLC after chemotherapy in the United States and is
commonly used for this indication.
In 2004, somatic activating mutations in the EGFR
gene were discovered.7–9 It has now been well documented
that these transforming mutations, which increase EGFR signal-
ing and cause a dependency on EGFR via a process known as
“oncogene addiction,” are associated with a several-fold in-
crease in response rates to EGFR TKIs and possibly increased
survival after treatment.10,11 Furthermore, there are clinical
characteristics that predict an increased chance of harboring a
mutation, namely, adenocarcinoma histology, history of never
smoking, female sex, and East Asian ethnicity.2–4,12 This sce-
nario, an identifiable molecular marker that predicts a marked
differential response to a given therapy, is an ideal one for
testing the promise of genotype-directed therapy. The geno-
type-directed strategy aims to abandon the traditional clinical
oncology approach of treating all patients with the same
histologic diagnosis under the same treatment algorithm in
favor of a more specific molecular analysis at the time of
diagnosis that has the power to elucidate optimal therapies for
each individual based on their own tumor biology.
GENOTYPE-DIRECTED THERAPY IN THE
FIRST-LINE METASTATIC SETTING
First-line therapy for advanced NSCLC is the clinical
setting in which EGFR genotype-directed therapy has been
most frequently tested to prove that the principle of the approach
is valid. Four studies have been published or presented in
abstract form that examine either gefitinib or erlotinib in previ-
ously untreated patients with advanced NSCLC known to harbor
EGFR mutations, as summarized in Table 1.13–16 There are
many notable differences in the design and results of these
four studies. Three of the studies use gefitinib, whereas the
Spanish study tested erlotinib. Two of the studies were
performed in Japan, which has a higher baseline incidence of
mutations than the European or North American population.
The US study was able to make up for this handicap by
incorporating clinical prescreening into their patient selection
algorithm (patients had to have at least one clinical criteria
associated with mutations before undergoing molecular testing),
resulting in the highest screen-positive rate of the four studies.
Two of the studies (those by Asahina et al.14 and
Sequist et al.16) were prospective trials that asked patients to
sign informed consent for study participation before molecular
screening; the other two protocol designs used pathology-based
screening for EGFR mutations with subsequent approach of
the corresponding patients to solicit consent for upfront
EGFR TKI therapy. As would be expected, the prospective
consent method resulted in a higher proportion of treatment
for the mutation-positive patients.
Although the two Japanese studies and the Spanish
study all considered only the most common EGFR mutations
(deletions in exon 19 and the exon 21 point mutation L858R)
as being indications for first-line EGFR TKIs, the US study
accepted patients with any identified somatic mutation in the
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TK region of EGFR. The 31 patients treated with gefitinib in
this study included 17 with exon 19 deletions, 9 with L858R,
2 patients with exon 20 insertion mutations, 1 patient with
concurrent L858R and T790M, 1 patient with L861Q, and 1
patient with G719A. The exon 20 insertion and the T790M
EGFR mutation subtypes have both been associated with resis-
tance to EGFR TKIs, although these discoveries were made after
the design and implementation of the US clinical trial.17–19
Likely as a result of the inclusion of these atypical mutations, the
US study had the lowest response rate to therapy for the four
trials, although this did not seem to adversely affect the observed
median progression-free survival estimates. Notably, 4 of the 5
patients with atypical mutations in the US study had stable
disease, lasting from 2 to 10 months.
There have been reports from retrospective cohorts that
patients with exon 19 deletion mutations have a longer overall
survival after treatment with gefitinib or erlotinib compared with
those with L858R mutations, although response rates among the
mutation subtypes do not seem to be statistically different.20,21
The four prospective studies of first-line EGFR TKI therapy
similarly compared response rates among these two mutation
types and found no significant difference. Only 2 of the 4 trials
(those by Pas-Arez et al.15 and Sequist et al.16) compared time to
progression among mutation subtypes, finding no clear differ-
ence, although the Spanish group observed a trend toward more
durable responses in the exon 19 deletion mutation group. None
of the prospective studies had the power to look at survival
differences among subgroups at the time of reporting.
Finally, it is worth noting that the toxic effects observed
among the 106 patients treated with first-line EGFR TKIs in
these four prospective studies was favorable compared with
the adverse events usually observed with standard first-line
combination chemotherapy for advanced NSCLC. Two patients
experienced nonfatal occurrences of interstitial lung disease, a
known but rare toxic effect of EGFR TKIs.22 Roughly 20% of
patients had grade 3 toxic effects, but there were no grade 4 toxic
effects in any of the cohorts. In contrast, chemotherapy typically
yields hematologic and gastrointestinal grade 3 to 4 toxic effects
in 25 to 75% of patients.23–25
Although these results are extremely promising, the use
of EGFR TKIs as first-line therapy in patients with advanced
NSCLC harboring EGFR mutations has not yet been studied
in a randomized controlled trial setting and therefore cannot
be considered a standard approach. It is thought that EGFR
mutations portend a more favorable biology and natural
history of advanced NSCLC regardless of therapy, so a trial
that incorporates a comparison arm is paramount in defining
the relative advantages of first-line TKIs.26–28 There are
several such trials in the development or ongoing throughout
the world and the results are anxiously awaited.
There are also several practical and logistical obstacles
to making genotype-directed therapy widely applicable. At
the current time, most diagnoses of advanced NSCLC are
made via fine-needle aspiration, which can pose technical
challenges for molecular analyses because of limited quantity
of tumor material. In addition, there is no standard accepted
method of genotyping for EGFR mutations, although several
methods have been proposed.29 To move toward a medical
system in which genotype-directed first-line therapy is uni-
versally feasible, the field needs to embrace a paradigm shift
and commit to obtaining larger core biopsy specimens at
diagnosis to provide sufficient material for multiple genetic
analyses. We also need to develop cheap, easy-to-use, sensi-
tive, and standardized methods of genotyping. If we can build
such a foundation, we will be able to quickly translate new
scientific advances into clinical practice, such as future dis-
coveries about molecular mechanisms of resistance to EGFR
TKIs and how this might change initial therapeutic recom-
mendations, and the development of second-generation agents
that target EGFR and how to choose among the various options
for an individual based on genotype analyses.
ADJUVANT THERAPY FOR NSCLC PATIENTS
HARBORING EGFR MUTATIONS
The next step in the development of genotype-directed
decision-making algorithms for NSCLC patients harboring
EGFR mutations is to study adjuvant therapy. Although
surgical resection is the backbone of therapy with curative
intent for early stage NSCLC, relapse rates after surgery are
suboptimal, ranging from 20 to 75% for stages I to III
disease.30 Adjuvant chemotherapy has been shown to provide
a modest benefit by reducing recurrence rates, but there is still
plenty of room for improvement.31,32 For a patient whose
resected tumor specimen is known to harbor an EGFR mu-
tation, it makes sense to ask if additional adjuvant treatment
with an EGFR TKI could be effective in treating micrometa-
static disease and further reducing the risk of relapse.
Our center is preparing to open a multicenter clinical
trial examining this approach in early-stage NSCLC. Patients
TABLE 1. Prospective Clinical Trials Using EGFR TKIs as First-Line Therapy in Advanced NSCLC Patients with EGFR Mutations
Author Country Drug Enrollment
No.
Screened
No. (%)
Positive
No. (%)
Treated Mutations
RR, %
(95% CI)
Median
F/U (mo)
Median
PFS (mo)
Median
OS (mo)
Inoue et al. Japan Gefitinib Pathology 75 25 (33) 16 (64) Classic 75 (54–96) 7.6 9.7 ––
Asahina et al. Japan Gefitinib Prospective 82 20 (24) 16 (80) Classic 75 (48–93) 12.7 8.9 ––
Pas-Arez et al. Spain Erlotinib Pathology 428 67 (19) 43 (64) Classic 82 (66–92) 7.0 13.3 ––
Sequist et al. United
States
Gefitinib Prospective 98 34 (35) 31 (91) Any 55 (33–70) 12.3 9.2 17.5
Pathology enrollment implies that the investigators screened a series of pathology specimens to find mutation-positive cases and then approached the patients to consider therapy.
Prospective enrollment implies that patients were consented for a clinical study that involved molecular screening, and then the mutation-positive patients underwent therapy. Classic
mutations refer to EGFR exon 19 deletion mutations and the exon 21 point mutation L858R.
CI, confidence interval; EGFR, epidermal growth factor receptor; F/U, follow-up; OS, overall survival; PFS, progression-free survival; RR, response rate; TKIs, tyrosine kinase inhibitors.
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with fully resected stage I to IIIA adenocarcinoma who also
have at least one other clinical predictor for EGFR mutations
(female sex, history of never smoking, East Asian ethnicity)
will be screened for exon 19 deletion or L858R EGFR
mutations. If positive, they will be treated with 24 months of
adjuvant erlotinib therapy to start within 6 months of surgery.
Adjuvant chemotherapy may precede the erlotinib at the
discretion of the investigator. The primary end point of the
study is 2-year disease-free survival, and we have powered
the study to detect a 20% increase in this end point compared
with historical data from published phase three adjuvant chemo-
therapy trials. We will also examine the safety and feasibility of
genotype-directed therapy in the adjuvant setting.
CONCLUSIONS
In summary, genotype-directed therapy is promising
for first-line treatment of advanced NSCLC, but practical
obstacles must be overcome before it can be widely applica-
ble and a randomized control trial is needed. Areas that
require future study include developing and testing a panel of
appropriate genotype analyses to be performed at diagnosis
that allow an oncologist to recommend optimal first-line
treatment regimens for patients with advanced NSCLC and
defining the role of EGFR TKIs in the adjuvant setting for
early-stage NSCLC.
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